[HTML][HTML] Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
A Sundlöv, KS Gleisner, J Tennvall… - European journal of …, 2022 - Springer
Abstract Purpose Radionuclide therapy with 177Lu-DOTATATE is well established for
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
A Sundlöv, KS Gleisner, J Tennvall… - European Journal of …, 2022 - lup.lub.lu.se
Purpose: Radionuclide therapy with 177 Lu-DOTATATE is well established for patients with
advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule …
advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule …
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
A Sundlöv, KS Gleisner, J Tennvall… - … Journal of Nuclear …, 2022 - portal.research.lu.se
Purpose: Radionuclide therapy with 177 Lu-DOTATATE is well established for patients with
advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule …
advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule …
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients.
A Sundlöv, KS Gleisner, J Tennvall… - European Journal of …, 2022 - europepmc.org
Purpose Radionuclide therapy with 177 Lu-DOTATATE is well established for patients with
advanced somatostatin receptor-positive neuroendocrine tumors with a standard schedule …
advanced somatostatin receptor-positive neuroendocrine tumors with a standard schedule …
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based Lu-DOTATATE treatment of NET patients
A Sundlöv, J Tennvall, CF Warfvinge… - European Journal of …, 2022 - inis.iaea.org
[en] Radionuclide therapy with 177 Lu-DOTATATE is well established for patients with
advanced somatostatin receptor-positive neuroendocrine tumors with a standard schedule …
advanced somatostatin receptor-positive neuroendocrine tumors with a standard schedule …
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
A Sundlöv, KS Gleisner, J Tennvall… - … journal of nuclear …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose Radionuclide therapy with 177 Lu-DOTATATE is well established for patients with
advanced somatostatin receptor-positive neuroendocrine tumors with a standard schedule …
advanced somatostatin receptor-positive neuroendocrine tumors with a standard schedule …
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients.
A Sundlöv, KS Gleisner, J Tennvall… - … Journal of Nuclear …, 2022 - search.ebscohost.com
Purpose: Radionuclide therapy with< sup> 177 Lu-DOTATATE is well established for
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
A Sundlöv, KS Gleisner, J Tennvall… - … Journal of Nuclear …, 2022 - search.proquest.com
Purpose Radionuclide therapy with 177 Lu-DOTATATE is well established for patients with
advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule …
advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule …
[HTML][HTML] Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
A Sundlöv, KS Gleisner, J Tennvall… - European Journal of …, 2022 - ncbi.nlm.nih.gov
Purpose Radionuclide therapy with 177 Lu-DOTATATE is well established for patients with
advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule …
advanced somatostatin receptor–positive neuroendocrine tumors with a standard schedule …